Advancements in the understanding of m7G Modification

Advancements in the understanding of m7G Modification

The 7-methylguanosine (m7G) cap, also known as m7G(5′)ppp(5′)X, is a specific structure located on the 5′-terminus of the eukaryotic mRNA and in certain viral RNAs. This cap structure is also found at the 5′-terminus of mRNA-like lncRNA and pri-miRNA. The m7G cap is primarily involved in the translation of mRNAs. It is also responsible for the stability of the mRNA, and promotes transcription, splicing, polyadenylation, and nuclear export of the mRNA.

The capped mRNAs are vital for functional host cells hence the degree of methylation on viral mRNA caps correlates with host mRNA cap methylation. A mechanism for viral caps is the formation of the 5′ 7-methylguanosine (m7G) cap structure by host enzymes such as guanylyl transferase (GTase), 5′ triphosphatase and methyltransferases. Consequentially, the inhibition of this strategy may prove to be a target for antiviral drugs (2-4).

Interestingly, there is more data that highlights the significant role of m7G modification in other human diseases, particularly cancer. Abnormal levels of m7G have been closely linked to the initiation and advancement of tumours through the regulation of multiple oncogenes and tumour suppressor genes. The precise molecular mechanisms underlying m7G modification in cancer are under research. Recent publications attempt to understand the potential role of m7G modifications in cancer and explore future diagnostic and therapeutic strategies related to m7G (1).

MBLI provides unique products for the discovery of RNA transcription and translation including monoclonal antibodies for methylguanosine (m7G)-Cap detection. They strive to partner with leading researchers to advance new technologies and applications.


Product CodeProduct Name SizeApplications:
RN017MAnti-7-methylguanosine (m7G) mAb200 μlDB, ELISA, ICC, IP, RIP, WB
RN016MAnti-7-methylguanosine (m7G)-Cap mAb200 μlDB, ELISA, ICC, IP, RIP, WB


  1. Sun, Dongyuan, et al. “Comprehensive analysis of circ RNA s for N7‐methylguanosine methylation modification in human oral squamous cell carcinoma.” FASEB BioAdvances (2023).
  2. Xie, Haiyun, et al. “METTL1 drives tumor progression of bladder cancer via degrading ATF3 mRNA in an m7G-modified miR-760-dependent manner.” Cell Death Discovery 8.1 (2022): 458.
  3. Walker, Alexander P, et al. “The SARS-COV-2 RNA Polymerase Is a Viral RNA Capping Enzyme.” Nucleic Acids Research, vol. 49, no. 22, 2021, pp. 13019–13030., doi:10.1093/nar/gkab1160.
  4. Garcia, Bea Clarise, et al. “Bud23–TRMT112 Interacts with the L Protein of Borna Disease Virus and Mediates the Chromosomal Tethering of Viral Ribonucleoproteins.” Microbiology and Immunology, vol. 65, no. 11, 2021, pp. 492–504., doi:10.1111/1348-0421.12934.
  5. Furuse, Yuki. “RNA Modifications in Genomic RNA of Influenza A Virus and the Relationship between RNA Modifications and Viral Infection.” International Journal of Molecular Sciences, vol. 22, no. 17, 2021, p. 9127., doi:10.3390/ijms22179127.

Information provided by MBL.

Caltag Medsystems is the distributor of MBL products in the UK and Ireland. If you have any questions about these products, please contact us.

Advancements in the understanding of m7G Modification
Tagged on:                 

Contact us